Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Lymphoma
NCT00201877Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Dec 2004
- Primary completion
- Jun 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in mantle cell lymphoma (MCL), follicular lymphoma (FL), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Dec 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00201877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201877.